Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
← catalyst calendarNCT06039241 · readout in 566 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
900estimated
Sites
55
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-07 | actual | When the study began enrolling |
| Primary completion | 2028-03-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-08 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFNumber of patients who maintain Eczema Area and Severity Index (EASI) ≤ 7 OR peak pruritus Numerical Rating Scale (NRS) ≤ 4 OR Dermatology Life Quality Index (DLQI) ≤ 5
measured From Month 6 to Month 12
Mean percent change from baseline in Atopic Dermatitis Control Tools (ADCT) score (≥12 years)
measured From baseline to Week 52
Mean percent change from baseline in Recap of atopic eczema (RECAP) score (6-11 years)
measured From baseline to Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed